Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years

To the Editor: In the MA.17R trial by Goss et al. (July 21 issue), 1 the rate of overall survival was not higher among women who received letrozole once a day for 5 years (accounting for more than 1800 pills) than among those who received placebo. The rates of contralateral breast cancer and of loca...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The New England journal of medicine 2016-10, Vol.375 (16), p.1590-1591
Hauptverfasser:	Sanz, Alvaro, del Valle, María L, Tempfer, Clemens, Ingle, James N, Parulekar, Wendy R
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Hormonal - therapeutic use Aromatase Aromatase - therapeutic use Aromatase Inhibitors - therapeutic use Breast cancer Breast Neoplasms - drug therapy Chemotherapy, Adjuvant Humans Mastectomy Medical prognosis Metastases Postmenopause Tamoxifen - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!